Development of a Predictive Model for Serious Adverse Drug Reaction in Psychiatric Patients Leading to the Use of Benztropine Injection by Using Data Mining Techniques
Main Article Content
Abstract
Objective: To develop a predictive model for an occurrence of serious adverse drug reactions, especially acute dystonia, leading to an administration of benztropine injection in psychiatric patients. Methods: Data of patients diagnosed with ICD10 F00.00 - F99.99, aging between 15 - 80 years old were gathered from Somdet Chaopraya institute of psychiatry’s database from January 2016 to December 2021. Subsequently, the collected data were then processed by a data selection algorithm with a predetermined set of variables to analyze the association with serious adverse drug reaction leading to an administration of benztropine injection. Data were then cleaned, and used to generate a predictive model by a decision tree method via RapidMiner Studio program. The program’s parameters were later adjusted for maximum precision. Results: This study gathered data of 41,713 patients with 5.47% of a serious adverse drug reaction leading to an administration of benztropine injection. A total of 164 variables were established with 16 being significant for generating the decision tree. The important first-class variable was an increase in antipsychotic drug dosage within 7 days which accounted for 91.39% of the serious adverse drug reaction. The other significant variables in the predictive model were the receiving of short-acting haloperidol injection or antipsychotic medication with a daily dosage equal to 5 mg/day of risperidone (sum DDD>5) with no concomitant anticholinergic drug. Development of the predictive model by a decision tree method from this study had shown to predict an occurrence of a serious adverse drug reaction with an accuracy of 84.32% and recall of 85.31%. Conclusion: Acute dystonia is a serious drug adverse reaction of antipsychotic medications with appropriate monitoring needed, particularly in patients with high-risk, i.e., those with the increased dosage of antipsychotic drugs within 7 days.
Article Details

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Crismon M, Kattura RS, Buckley PF. Schizophrenia. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. editors. Pharmacotherapy: a pathophy siologic approach. 10th ed. New York, NY: McGraw Hill; 2017.
Mazurek MF, Rosebush PI. Acute drug-induced dystonia. In: Factor S, Lang A, Weiner W, editors. Drug induced movement disorders. 2nd ed. Boston, MA: Blackwell Publishing; 2005. p.72-102.
Annamalai A. Medical management of psychotropic side effects. New York, NY: Springer; 2017. p.235-244.
Blanchet PJ. Antipsychotic drug-induced movement disorders. Can J Neurol Sci. 2003; 30: S101-7.
Campbell D. The management of acute dystonic reactions. Aust Prescr. 2001; 24: 19-20.
Mathews M, Gratz S, Adetunji B, George V, Mathews M, Basil B. Antipsychotic-induced movement disor- ders: evaluation and treatment. Psychiatry(Edgmont) 2005; 2: 36-41.
Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. Medication adherence in schizophre- nia: factors influencing adherence and consequen- ces of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013; 3: 200-18.
Phan SV. Medication adherence in patients with schizophrenia. Int J Psychiatry Med. 2016; 51: 211-19.
Ostroumova TM, Tolmacheva VA, Ostroumova OD, Parfenov VA. Drug-induced dystonia. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(5):4-8.
Suzuki T, Matsuzaka H. Drug-induced Pisa syn drome (pleurothotonus): epidemiology and manage- ment. CNS Drugs. 2002; 16: 165-74.
Addonizio G, Alexopoulos GS. Drug-induced dysto nia in young and elderly patients. Am J Psychiatry. 1988; 145: 869-71.
Tarsy D. Movement disorders with neuroleptic drug treatment. Psychiatr Clin North Am. 1984; 7: 453-71.
van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ. 1999; 319: 623-26.
Wirshing WC. Movement disorders associated with neuroleptic treatment. J Clin Psychiatry. 2001; 62 Suppl 21: 15-8.
Defazio G, Berardelli A, Abbruzzese G, Coviello V, Carella F, De Berardinis MT, et al. Risk factors for spread of primary adult onset blepharospasm: a multicentre investigation of the Italian movement disorders study group. J Neurol Neurosurg Psychia- try. 1999; 67: 613-9.
Park HW, Kwak JR, Lee JS. Clinical characteristics of acute drug-induced dystonia in pediatric patients. Clin Exp Emerg Med. 2017; 4: 133-7.
Loonen AJ, Ivanova SA. Neurobiological mecha- nisms associated with antipsychotic drug-induced dystonia. J Psychopharmacol. 2021; 35: 3-14.
Spina E, Sturiale V, Valvo S, et al. Prevalence of acute dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis. Int Clin Psychopharmacol. 1993; 8: 21-4.
Satterthwaite TD, Wolf DH, Rosenheck RA, Gur RE, Caroff SN. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsy chotics for the treatment of agitation. J Clin Psychia try. 2008; 69: 1869-79.
Taylor D, Young A, Barnes TE. The Maudsley prescribing guidelines in psychiatry. New York. Wiley-Blackwell; 2018.
Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L. Suggested minimal effective dose of risperi done based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry. 1999; 156: 869-75.
Charoenchokthavee W, Panomvana D, Sriuranpong V, Areepium N. Prevalence of CYP2D6*2, CYP2D6 *4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment. Breast Cancer (Dove Med Press). 2016; 8: 149-55.
Hongkaew Y, Gaedigk A, Wilffert B, et al. Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone. Sci Rep. 2021; 11: 4158.
Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000; 157: 514-20.